Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 24, 2025 (GLOBE NE ...

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A securities class action lawsuit has been filed against 3D Systems Corporation for allegedly making materially false and misleading statements during the Class Period from August 13, 2024, to May 12, 2025 [1][2]. Financial Performance - 3D Systems reported disappointing financial results for Q4 and full-year 2024, with a non-GAAP EPS of -$0.19, missing consensus by $0.08 per share [9]. - Sales revenue for Q4 2024 was $111 million, down 3.4% year-over-year, and missed estimates by $4.17 million [9]. - Full-year 2024 revenue totaled $440.1 million, reflecting a 10% decline from the prior year, primarily due to weaker hardware system sales [9]. - A $9 million revenue reduction in Q4 was attributed to changes in accounting estimates related to the Regenerative Medicine Program [9]. Stock Price Reaction - Following the announcement of disappointing Q4 results on March 26, 2025, shares of 3D Systems fell by 20.96%, closing at $2.15 per share on March 27, 2025 [3]. - After the May 12, 2025 press release regarding Q1 2025 results, the stock price dropped by $0.68 per share, or 26.6%, closing at $1.87 per share on May 13, 2025 [5]. Issues Raised in the Lawsuit - The lawsuit alleges that 3D Systems understated the impact of weakened customer spending and overstated its resilience amid challenging industry conditions [9]. - Revised milestone criteria in the United Partnership are expected to adversely affect revenues from the Regenerative Medicine Program [9]. - The company's public statements were deemed materially misleading due to these factors [9].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific allegations include: - Overestimation of revenue from pre-spin projects [3]. - Overstatement of cost savings from exiting TSAs [3]. - Inflated EBITDA targets for 2025 [3]. - Overstated viability of Fortrea's post-spin business model [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, leading to a stock price drop of over 12% [4]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to neutral, resulting in an 8% decline in stock price after the company canceled two scheduled conferences [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming and negatively impacting financial performance [6]. - Following this announcement, Fortrea's stock price fell by more than 25% [6].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors about its business prospects, particularly regarding customer spending and revenue impacts from updated milestone criteria in its Regenerative Medicine Program [1][2]. Financial Performance - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million. The company also reported a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, worse than the consensus estimate of a loss of $0.14 per share, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The company withdrew its full-year 2025 outlook due to prolonged softness in customer capital spending and macroeconomic uncertainty, resulting in a further stock price decline of $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm for legal options [1]. - The court-appointed lead plaintiff will represent the interests of the class and any member can move to serve as lead plaintiff [7]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false statements and failing to disclose critical information about the ENVISION clinical study [4]. - Specific allegations include the study's lack of a concurrent control arm, which undermined the ability to demonstrate the drug's effectiveness, and the company's disregard for FDA warnings regarding study design [4]. - As a result of these issues, there was a substantial risk that the new drug application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's prospects [4]. Group 3: Stock Price Impact - Following the FDA's briefing document questioning the effectiveness of UGN-102, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [5]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, the stock price dropped by $3.37, or 44.7%, closing at $4.17 per share on May 21, 2025 [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...